BioOrbit Company Profile

Background

Overview

BioOrbit Ltd, established in 2023 and headquartered in London, United Kingdom, is a pioneering biotechnology company specializing in the development of hardware for the large-scale crystallization of protein drugs in microgravity environments. The company's mission is to revolutionize pharmaceutical manufacturing by harnessing the unique properties of space to produce high-quality, concentrated protein crystals suitable for subcutaneous administration. This innovation aims to enhance patient convenience and accessibility to treatments, particularly for conditions like cancer.

Mission and Vision

BioOrbit's mission is to become the leading pharmaceutical manufacturing facility in microgravity, contributing to the space manufacturing revolution. The company's vision is to establish a pharmaceutical factory in space within the next decade, enabling patients to self-administer treatments from the comfort of their homes.

Industry Significance

BioOrbit operates at the intersection of biotechnology and aerospace, addressing a critical challenge in pharmaceutical manufacturing: the production of high-concentration, low-viscosity biologic formulations suitable for subcutaneous delivery. By leveraging microgravity to enhance protein crystallization, BioOrbit is poised to transform the administration of complex biologic drugs, making treatments more accessible and less invasive.

Key Strategic Focus

Core Objectives

Development of Space-Based Manufacturing Platforms: Design and deploy hardware capable of crystallizing protein drugs in microgravity environments.

Enhancement of Drug Formulations: Utilize microgravity to produce uniform, high-quality protein crystals, facilitating the transition from intravenous to subcutaneous drug administration.

Commercialization and Scalability: Establish a scalable process for in-space drug manufacturing, aiming for large-scale production within the next decade.

Areas of Specialization

Protein Crystallization in Microgravity: Developing technologies to crystallize protein drugs in space, improving their quality and suitability for subcutaneous delivery.

Pharmaceutical Manufacturing in Space: Pioneering the use of space environments for the production of biologic drugs, addressing challenges associated with Earth-based manufacturing.

Key Technologies Utilized

Microgravity Crystallization Platforms: Hardware designed to operate in space, enabling the crystallization of protein drugs without the interference of gravity-induced convection and sedimentation.

Autonomous Manufacturing Systems: Systems capable of conducting continuous, large-scale production of protein crystals in space, from grams to hundreds of kilograms annually.

Primary Markets Targeted

Pharmaceutical Industry: Collaborating with pharmaceutical companies to enhance the quality and delivery methods of biologic drugs.

Healthcare Providers: Providing solutions that enable patients to self-administer treatments, reducing the need for hospital visits.

Financials and Funding

Funding History

BioOrbit has completed two funding rounds, securing investments from notable venture capital firms and accelerators. The company has been supported by organizations such as Seraphim Space Accelerator, which focuses on space technology startups.

Total Funds Raised

Specific details regarding the total funds raised by BioOrbit are not publicly disclosed.

Notable Investors

Seraphim Capital: A leading venture capital firm specializing in space technology investments.

Airbus Accelerator: Provided support through the Airbus UK Space Accelerator program, aiding in the development of BioOrbit's crystallization hardware.

Intended Utilization of Capital

The funds raised are intended to support the development and deployment of BioOrbit's space-based manufacturing platforms, including the design and launch of hardware for protein crystallization in microgravity environments. Additionally, capital is allocated for pre-clinical trials and regulatory compliance efforts.

Pipeline Development

Key Pipeline Candidates

Monoclonal Antibody Therapies: Focusing on the crystallization of antibody-based cancer treatments in space to improve their quality and facilitate subcutaneous administration.

Stages of Development

Proof-of-Concept Demonstration: Scheduled for early 2025, involving the launch of a payload to the International Space Station (ISS) to validate the crystallization process in microgravity.

Pre-Clinical Trials: Planned for 2026 or 2027, focusing on evaluating the efficacy and safety of space-manufactured protein crystals.

Target Conditions

Cancer: Particularly focusing on antibody-based therapies for various types of cancer, aiming to enhance treatment efficacy and patient convenience.

Anticipated Milestones

2025: Launch of proof-of-concept payload to the ISS.

2026-2027: Initiation of pre-clinical trials for space-manufactured protein crystals.

Technological Platform and Innovation

Proprietary Technologies

Microgravity Crystallization Hardware: Custom-designed equipment capable of operating in space to facilitate the crystallization of protein drugs without gravitational interference.

Significant Scientific Methods

Microgravity Crystallization: Utilizing the unique conditions of space to produce uniform, high-quality protein crystals, enhancing drug stability and efficacy.

Autonomous Manufacturing Systems: Developing systems capable of conducting continuous, large-scale production of protein crystals in space, from grams to hundreds of kilograms annually.

Leadership Team

Katie King – Co-Founder & CEO

Dr. Katie King holds a PhD in nanomedicine from the University of Cambridge and has experience working at NASA and AstraZeneca. She is a strong believer in using science in a microgravity environment to accelerate healthcare and drug development on Earth.

Competitor Profile

Market Insights and Dynamics

The pharmaceutical manufacturing industry is undergoing significant transformation, with increasing interest in space-based drug production. The global biopharmaceuticals market is expanding, driven by the demand for innovative therapies and the potential of space manufacturing to enhance drug quality and delivery methods.

Competitor Analysis

SpacePharma: Specializes in microgravity research platforms that can host various experiments on the ISS.

LambdaVision: Working on manufacturing artificial retinas within the unique environment of space, with the aim of restoring lost vision.

Varda Space Industries: Sent a pharma manufacturing capsule into space to test a crystallization process for HIV therapy ritonavir.

Strategic Collaborations and Partnerships

BioOrbit has engaged in strategic collaborations to advance its mission:

European Space Agency (ESA): Through the ESA Business Incubation Centre UK, BioOrbit has received support for technology development and business growth.

Airbus UK Space Accelerator: Provided support through the Airbus UK Space Accelerator program, aiding in the development of BioOrbit's crystallization hardware.

Operational Insights

BioOrbit's focus on space-based pharmaceutical manufacturing positions it uniquely in the market, offering a novel approach to drug production that leverages microgravity to enhance protein crystallization. This innovation addresses challenges in traditional drug manufacturing, such as the need for high-quality, concentrated biologic formulations suitable for subcutaneous delivery.

Strategic Opportunities and Future Directions

BioOrbit's strategic roadmap includes:

Expansion of Space-Based Manufacturing Capabilities: Developing and deploying additional hardware for protein crystallization in microgravity environments.

Regulatory Compliance and Market Entry: Navigating regulatory pathways to bring space-manufactured drugs to market, ensuring safety and efficacy.

Partnerships with Pharmaceutical Companies: Collaborating with industry leaders to integrate space-manufactured protein crystals into existing drug development pipelines.